Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?

 
• By Alexandra Shimmings

AbbVie's investigational monoclonal antibody therapy risankizumab has triumphed against its competitors in three Phase III trials in psoriasis, but will it be too late to the party to enjoy the full commercial benefits?

Carnival End_1200
Too late to the party for risankizumab • Source: Shutterstock

More from Clinical Trials

More from R&D